残留颅内脑膜瘤的体积增长与生长曲线分析
该研究回顾性分析了2004至2020年间在一家三级神经外科中心识别的236例残留脑膜瘤患者,采用手动分割测量术后及每次随访MRI的肿瘤体积。中位随访5.3年间,绝对增长率为每年0.11 cm³,相对增长率为每年4.3%;56.0%的患者按RANO标准(体积增加40%)判定为进展,颅底位置(HR 1.60)和Ki-67指数升高(HR 3.43)与进展相关。
要点
- 残留脑膜瘤绝对增长率每年0.11 cm³,相对增长率每年4.3%。
- 56.0%患者按RANO标准进展,仅5.5%出现临床进展。
- 颅底位置(HR 1.60)和Ki-67指数升高(HR 3.43)与进展相关。
核心结论
- 残留脑膜瘤的绝对和相对增长率较低,但多数符合RANO进展标准。
- 肿瘤位置和Ki-67指数可用于分层辅助治疗和监测方案。
研究设计与样本
- 回顾性队列研究,纳入2004至2020年间在一家三级神经外科中心识别的残留脑膜瘤患者236例。
- 肿瘤体积通过手动分割测量,术后及每次随访MRI均进行测量。
- 增长率采用线性混合效应模型和非线性回归分析生长轨迹确定。
- 进展根据RANO标准(体积增加40%)定义。
主要发现
- 236例残留脑膜瘤患者中,132例(56.0%)按RANO标准进展,其中86例(65.2%)进展后接受保守管理。
- 13例(5.5%)出现临床进展。
- 中位随访5.3年(四分位距3.5-8.6年)期间,绝对增长率为每年0.11 cm³,相对增长率为每年4.3%。
- 多变量Cox回归分析中,与残留脑膜瘤进展相关的因素为颅底位置(风险比[HR] 1.60,95%CI 1.02-2.50)和Ki-67指数升高(HR 3.43,95%CI 1.19-9.90)。
- 大多数脑膜瘤呈现指数和逻辑斯蒂生长模式(中位R²值0.84,95%CI 0.60-0.90)。
关键数值与推荐
- 进展定义:RANO标准,即体积增加40%。
- 绝对增长率:每年0.11 cm³;相对增长率:每年4.3%。
- 颅底位置:HR 1.60(95%CI 1.02-2.50);Ki-67指数升高:HR 3.43(95%CI 1.19-9.90)。
- 生长模式拟合中位R²值0.84(95%CI 0.60-0.90)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: After meningioma surgery, approximately 1 in 3 patients will have residual tumor that requires ongoing imaging surveillance. The precise volumetric growth rates of these tumors are unknown. OBJECTIVE: To identify the volumetric growth rates of residual meningioma, growth trajectory, and factors associated with progression. METHODS: Patients with residual meningioma identified at a tertiary neurosurgery center between 2004 and 2020 were retrospectively reviewed. Tumor volume was measured using manual segmentation, after surgery and at every follow-up MRI scan. Growth rates were ascertained using a linear mixed-effects model and nonlinear regression analysis of growth trajectories. Progression was defined according to the Response Assessment in Neuro-Oncology (RANO) criteria (40% volume increase). RESULTS: There were 236 patients with residual meningioma. One hundred and thirty-two patients (56.0%) progressed according to the RANO criteria, with 86 patients being conservatively managed (65.2%) after progression. Thirteen patients (5.5%) developed clinical progression. Over a median follow-up of 5.3 years (interquartile range, 3.5-8.6 years), the absolute growth rate was 0.11 cm 3 per year and the relative growth rate 4.3% per year. Factors associated with residual meningioma progression in multivariable Cox regression analysis were skull base location (hazard ratio [HR] 1.60, 95% CI 1.02-2.50) and increasing Ki-67 index (HR 3.43, 95% CI 1.19-9.90). Most meningioma exhibited exponential and logistic growth patterns (median R 2 value 0.84, 95% CI 0.60-0.90). CONCLUSION: Absolute and relative growth rates of residual meningioma are low, but most meet the RANO criteria for progression. Location and Ki-67 index can be used to stratify adjuvant treatment and surveillance paradigms.
引用
- Gillespie CS, Richardson GE, Mustafa MA, et al. Volumetric Growth and Growth Curve Analysis of Residual Intracranial Meningioma. Neurosurgery. 2022. PMID: 36656062. doi:10.1227/neu.0000000000002268
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。